Table 2 Pregnancy outcomes
From: sFlT-1/PlGF ratio as a predictor of preeclampsia in COVID-19 pregnant patients
Variable | Control group | Study group | p |
|---|---|---|---|
Number of patients, n (%) | 57 (45,6) | 68 (54,4) | |
cesarean section, n (%) | 18 (31,57) | 23 (33,82) | 0.707** |
Diagnosis of hipertension, n (%) | 25 (35,08) | 26 (38,23) | 0.677** |
Clinical symptoms of preeclampsia, n (%) | 6 (10,52) | 5 (7,35) | 0.799** |
Diagnosis of preeclampsia, n (%) | 10 (17,54) | 10 (14,7) | 0.852** |
HELLP, n (%) | 0(0) | 1 (1,47) | 1*** |
Eclampsia, n (%) | 0(0) | 0(0) | |
DIC, n (%) | 0(0) | 0(0) | |
sFlt-1/PlGF > 38, n (%) | 15 (26,31) | 20 (29,41) | 0.854** |
Odds of developing PE in patients with sFlt-1/PlGF > 38 (OR) | 11,38 | 4.71 | 0.030**** 0,002**** |